A decade after its first FDA approval, Takeda expands label of HyQvia to include rare autoimmune disorder
The FDA on Monday extended the label for Takeda’s HyQvia (immune globulin infusion 10% [human] with recombinant human hyaluronidase) as a maintenance therapy to prevent …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
